title: Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics.
abstract: BACKGROUND
  Although tissue plasminogen activator (tPA) has been approved for use in acute ischemic stroke, concerns linger regarding its safety. We analyzed whether patients in special subgroups (i.e., age >70 years, baseline National Institute of Health Stroke Scale (NIHSS) score >20, diabetes, congestive heart failure (CHF), and of Hispanic origin) have a higher risk of symptomatic intracerebral hemorrhage (SICH) than patients without these characteristics.
  
  
  METHODS
  Four prospective observational studies of acute ischemic stroke patients treated within 3 h with Alteplase were identified and individual patient data were pooled for this analysis. These included the Standard Treatment with Alteplase to Reverse Stroke Study [STARS, N = 389], Epidemiology Study of Ischemic Stroke [ESIS, N = 236], University Of Texas Houston Stroke Study [UT, N = 241], and Canadian Activase For Stroke Effectiveness Study [CASES, N = 1100]. The risk of SICH was calculated for all patients and for each of five subgroups.
  
  
  RESULTS
  A total of 1966 patients were studied. Overall the risk of symptomatic ICH was 4.7% (95%CI, 3.8-5.8%) and the risk was similar among patients with and without each of the five characteristics. Patients with advanced age, baseline NIHSS score >20, CHF or diabetes had increased mortality and significantly lower rate of functional recovery.
  
  
  CONCLUSIONS
  The present study suggests that these specified subgroups of patients are not at increased risk of SICH after stroke thrombolysis compared to those without these characteristics.
authors.affiliation: Calgary Stroke Program, Department of Clinical Neurosciences, Foothills Medical Center, University of Calgary, Calgary, Alberta, Canada.
authors.forename: P N
authors.initials: PN
authors.lastname: Sylaja
authors.forename: Wei
authors.initials: W
authors.lastname: Dong
authors.forename: James C
authors.initials: JC
authors.lastname: Grotta
authors.forename: Mary K
authors.initials: MK
authors.lastname: Miller
authors.forename: Kristen
authors.initials: K
authors.lastname: Tomita
authors.forename: Scott
authors.initials: S
authors.lastname: Hamilton
authors.forename: Charles
authors.initials: C
authors.lastname: Semba
authors.forename: Michael D
authors.initials: MD
authors.lastname: Hill
mesh_terms: D000368:Aged; D002545:Brain Ischemia / Q000150:complications*; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D048909:Diabetes Complications; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications; D006630:Hispanic or Latino; D006801:Humans; D011446:Prospective Studies; D020127:Recovery of Function; D018570:Risk Assessment; D012720:Severity of Illness Index; D020521:Stroke / Q000150:complications / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology; D010959:Tissue Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator